Expression of genes coding for the tumor necrosis factor and lymphotoxin ligand-receptor system in non-Hodgkin's lymphomas

2000 ◽  
Vol 49 (9) ◽  
pp. 469-475 ◽  
Author(s):  
Krzysztof Warzocha ◽  
Patricia Ribeiro ◽  
Nathalie Renard ◽  
Jacques Bienvenu ◽  
Carloe Charlot ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Receptor System ◽  
Expression Of Genes ◽  
Hodgkin's Lymphomas ◽  
Necrosis Factor

Tumor necrosis factor promoter gene polymorphism associated with increased susceptibility to non-Hodgkin's lymphomas

2006 ◽  
Vol 0 (0) ◽  
pp. 061114074547005-??? ◽  
Author(s):  
Besma Bel Hadj Jrad ◽  
Amel Chatti ◽  
Adnene Laatiri ◽  
Slim Ben Ahmed ◽  
Abdelaziz Romdhane ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Gene Polymorphism ◽  
Tumor Necrosis ◽  
Promoter Gene ◽  
Hodgkin's Lymphomas ◽  
Necrosis Factor ◽  
Increased Susceptibility

Factors That Predict Chemotherapy-Induced Myelosuppression in Lymphoma Patients: Role of the Tumor Necrosis Factor Ligand-Receptor System

2000 ◽  
Vol 18 (2) ◽  
pp. 325-325 ◽  
Author(s):  
Eric Voog ◽  
Jacques Bienvenu ◽  
Krzysztof Warzocha ◽  
Isabelle Moullet ◽  
Charles Dumontet ◽  
...  
Keyword(s):  
Growth Factor ◽  
Tumor Necrosis Factor ◽  
Febrile Neutropenia ◽  
Tumor Necrosis ◽  
Performance Status ◽  
Receptor System ◽  
Who Grade ◽  
High Doses ◽  
Necrosis Factor

PURPOSE: To analyze factors that predict the occurrence of chemotherapy-induced myelosuppression and, in particular, the role of the tumor necrosis factor (TNF) ligand-receptor system in lymphoma patients at the beginning of their treatment. PATIENTS AND METHODS: We investigated the predictive factors for myelosuppression after the first course of chemotherapy in a cohort of 101 consecutive, previously untreated lymphoma patients receiving regimens that include doxorubicin and cyclophosphamide. Plasma samples were tested at baseline by enzyme-linked immunosorbent assay for TNF and its soluble receptors. Univariate and multivariate analyses were performed with a forward regression procedure that included all of the parameters that were found to be significant in the univariate analysis. The dose of chemotherapy and the prophylactic treatment with granulocyte colony-stimulating factor were deliberately included in this model. RESULTS: Sixty-seven patients experienced World Health Organization (WHO) grade 4 neutropenia, and 37 patients experienced febrile neutropenia, which was responsible for WHO grade 2 through 4 infections in 23 patients. In multiparametric regression analysis, the occurrence of grade 4 neutropenia was associated with high doses of cyclophosphamide (odds ratio [OR], 19.8; P = .008) and high levels of soluble p75-R-TNF (OR, 8.52; P = .001). The duration of grade 4 neutropenia for more than 5 days was associated with the lack of hematopoietic growth factor administration (OR, 6.76; P = .004) and high levels of soluble p75-R-TNF (OR, 5.84; P = .0023). The occurrence of febrile neutropenia was associated with high doses of cyclophosphamide (OR, 4.7; P = .007), altered performance status (OR, 18.8; P < .0001) and high levels of soluble p75-R-TNF (OR, 3.49; P = .029). CONCLUSION: This study indicates that in addition to the dose of chemotherapy and the administration of hematopoietic growth factors, poor performance status and high p75-R-TNF levels can predict the occurrence of chemotherapy-induced myelosuppression in lymphoma patients. This model may help in selecting patients for prophylactic growth factor administration.

Sign in / Sign up

Export Citation Format

Share Document